Tirzepatide purity and testing: what buyers should verify

Last updated 2026-07-27

What does "purity" actually mean for tirzepatide?

Purity means the vial contains what the label says, at the stated concentration, without meaningful amounts of degradation products, residual solvents, heavy metals, or bacterial endotoxin. For a peptide drug like tirzepatide, that's a taller order than it sounds. Peptides degrade with heat, light, and time, and synthesis byproducts (truncated sequences, deamidated forms, trifluoroacetate salts left over from purification) can show up even in a technically "successful" batch. The FDA-approved products, Mounjaro and Zepbound, both use the tirzepatide active ingredient manufactured under Lilly's own controlled process and reviewed against the standards in the United States Pharmacopeia (USP) monograph system and FDA's own chemistry, manufacturing, and controls (CMC) review as part of the New Drug Application. That review covers identity, strength, quality, and purity testing before the drug is ever approved ^[1]. Compounded tirzepatide is a different animal. It's made by a compounding pharmacy from bulk active pharmaceutical ingredient (API), not reviewed by FDA before it reaches a patient, and legally exists in a gray zone that opened up during the Mounjaro/Zepbound shortage. FDA removed tirzepatide from its drug shortage list in December 2024, which legally narrowed the basis many compounders had relied on for producing copies ^[2]. Some 503A and 503B pharmacies still compound it under other legal pathways (patient-specific formulation changes, or verified non-shortage stock), but the purity assurance now rests entirely on that specific pharmacy's own testing program, not an FDA seal of approval.

Is FDA-approved tirzepatide (Mounjaro, Zepbound) tested differently than compounded versions?

Yes, substantially. Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management) went through full New Drug Applications, meaning Lilly had to submit stability data, impurity profiles, and manufacturing validation for FDA reviewers before approval. Every commercial batch after approval is also subject to FDA's routine post-market surveillance and Lilly's internal quality control, governed by Current Good Manufacturing Practice (CGMP) regulations at 21 CFR Part 211 ^[3]. Compounded tirzepatide has no equivalent pre-market review. A 503A pharmacy compounds for an individual patient prescription and is regulated mostly at the state board of pharmacy level, with FDA oversight limited largely to enforcement actions. A 503B outsourcing facility is a step up: it registers with FDA, must follow CGMP-like standards under section 503B of the Food, Drug, and Cosmetic Act, and is subject to more routine FDA inspection ^[4]. If you're going the compounded route at all, a 503B-registered facility with inspection history you can actually look up is the more defensible choice over an unregistered 503A operation you've never heard of. Neither pathway guarantees purity by itself. Registration status tells you who is legally accountable and inspectable, not what's actually in a specific vial you're about to inject.

What does a Certificate of Analysis (CoA) actually prove, and what does it not prove?

A Certificate of Analysis is a lab report tied to one specific manufacturing batch, showing test results against a defined set of specifications: usually identity (is it tirzepatide, confirmed by mass spectrometry or HPLC), purity percentage, presence of specific impurities, sterility, and endotoxin level. A real CoA proves that one tested sample from one batch met those specs on the day it was tested. It does not prove every vial in that batch is identical, doesn't prove the product hasn't degraded since testing, and doesn't prove anything about a different batch with a different lot number. Purity numbers also mean nothing without knowing the test method: USP has published reference standards and testing methods specific to tirzepatide impurities, and a CoA that doesn't name a method (HPLC-UV, LC-MS, etc.) is much weaker evidence than one that does ^[5]. Red flags in a CoA: no lot number, no test date, no named lab, a purity figure with no stated method, or a CoA that's clearly a stock document reused across different batches. If a source can't produce a batch-matched CoA on request, that's a real problem, not a technicality. A legitimate third-party lab CoA should ideally come from an ISO/IEC 17025 accredited facility, the international standard for testing and calibration laboratory competence ^[6]. That accreditation doesn't test the product itself, it tests whether the lab's own processes are trustworthy enough that its results mean something.

What purity percentage should tirzepatide actually test at?

For pharmaceutical-grade tirzepatide, industry and compendial expectations generally sit at 98% or higher purity by HPLC, with tightly controlled limits on individual and total impurities. USP monograph work for tirzepatide, developed as part of the broader push to standardize testing after demand surged, sets defined acceptance criteria for identification, assay (potency), and impurities rather than a single round number marketed as "purity" ^[5]. Be skeptical of any seller advertising "99.9% pure" as a headline claim with no batch-specific documentation behind it. That figure, even if true for one sample, tells you nothing about the vial you'd actually receive. It's also worth knowing that "purity" as tested on bulk API before compounding is a different measurement than a finished, reconstituted, multi-dose vial that's been through shipping, storage, and repeated needle punctures over weeks of use. Both numbers matter; sellers usually only show you the first one, if any. A useful gut check: ask what percentage figure appears on the actual CoA for the lot you'd receive, not a general marketing claim, and ask whether that number is assay potency (how much active drug is present) or purity (how much of what's present is the intended compound versus byproducts). Those are different tests measuring different things, and conflating them is a common way vague claims get made to sound more rigorous than they are.

How do you verify a supplier's purity and testing claims before buying?

Ask directly for the batch-specific CoA tied to the lot number you'd actually receive, not a generic template. Confirm the testing lab is named and, ideally, ISO 17025 accredited; you can often verify accreditation status through the lab's own published scope of accreditation. Check whether the pharmacy is a registered 503B outsourcing facility. FDA maintains information on registered outsourcing facilities, and state boards of pharmacy license 503A compounding pharmacies; you can look up license status and any disciplinary history through your state board ^[4]. Ask whether the product requires a prescription and clinical intake. A pharmacy or telehealth platform that skips a real medical evaluation, doesn't ask about thyroid cancer family history, gallbladder disease, or pancreatitis history, is skipping the same screening that legitimate prescribing requires, regardless of how clean their lab paperwork looks. Be wary of research-chemical sellers marketing tirzepatide "for lab use only" or "not for human consumption" while clearly targeting individual buyers online. This labeling is often a legal workaround, not a genuine research context, and these products typically carry no clinical oversight, no verified CoA tied to what you receive, and no prescriber accountable if something goes wrong. If you want the FDA-approved path with proper clinical oversight, review Tirz Rx dosage information and work through a provider-reviewed intake process rather than an anonymous online storefront.

What are the real risks if tirzepatide isn't pure or is mishandled?

Three broad risk categories matter here: wrong dose (under- or over-concentrated product), contamination (bacterial, endotoxin, particulate), and degradation (heat- or light-damaged peptide that's lost potency or formed new byproducts). Under-dosing from a diluted or degraded product wastes money and stalls progress, which is frustrating but not dangerous. Over-concentration is more concerning: tirzepatide dosing in the SURMOUNT and SURPASS trials was carefully titrated from 2.5 mg up to a maximum of 15 mg weekly specifically because higher doses increase GI side effects and other adverse events, and an inaccurately concentrated vial defeats that titration logic entirely ^{[7] [8]}. Contamination risk is why proper reconstitution and storage technique matters as much as sourcing. Unopened vials of Zepbound can be stored in the refrigerator (36°F to 46°F) until the expiration date, or at room temperature for up to 21 days according to the manufacturer's guidance ^[7]. Compounded products, mixed from lyophilized powder, generally carry their own beyond-use dating from the compounding pharmacy, and improper reconstitution technique (non-sterile water, contaminated needles, warm storage) can introduce bacterial growth that a purity test done before mixing would never catch. If you're compounding at home, how to reconstitute Tirz Rx and Tirz Rx how to inject cover the technique side of this; purity testing on paper doesn't protect you from a dirty reconstitution.

What does the FDA-approved evidence actually show tirzepatide does?

Tirzepatide is a dual GIP/GLP-1 receptor agonist, and it's genuinely one of the better-evidenced drugs in the weight-loss and diabetes space right now, which is part of why the purity question matters so much: people are chasing real, trial-documented results. In the SURMOUNT-1 trial (NCT04184622), adults with obesity or overweight without diabetes lost an average of 20.9% of body weight on the 15 mg dose over 72 weeks, compared with 3.1% on placebo ^[9]. In SURPASS-2 (NCT03987919), tirzepatide outperformed semaglutide 1 mg for both glycemic control and weight loss in adults with type 2 diabetes over 40 weeks ^[10]. These are the trials underlying FDA approval of Mounjaro (2022, for type 2 diabetes) and Zepbound (2023, for chronic weight management). Compounded tirzepatide, even if perfectly pure, hasn't been studied in its own randomized trials; it rides on the reputation of the branded product's evidence without the same manufacturing assurance behind it. That's not automatically disqualifying, but it's a real gap buyers should be honest with themselves about.

What are the known side effects and contraindications, regardless of source purity?

No amount of purity testing changes tirzepatide's underlying side effect and safety profile, because these are pharmacologic, not contamination-related. The most common side effects across the SURMOUNT and SURPASS trials were gastrointestinal: nausea, diarrhea, constipation, and vomiting, generally more frequent during dose escalation ^{[9] [10]}. Both Mounjaro and Zepbound carry a boxed warning for thyroid C-cell tumors, based on findings in rodent studies; tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[7]. The prescribing information also flags risk of pancreatitis, gallbladder problems (including gallstones), acute kidney injury (often secondary to GI-related dehydration), and diabetic retinopathy complications in patients with existing type 2 diabetes and retinopathy ^[7]. This is exactly why a real clinical intake matters more than a CoA. A lab report can confirm what's in the vial. It can't screen your personal and family medical history for MTC, evaluate whether you have active gallbladder disease, or catch a pancreatitis history that makes tirzepatide inappropriate for you specifically. That screening only happens with a real prescriber, and it's a bigger safety lever than purity testing alone.

Does purity affect how well tirzepatide works, or how long a cycle should run?

A properly dosed, pure product should perform consistent with trial data at the equivalent dose and duration; a degraded or under-concentrated product simply delivers less active drug than the number on the label implies, which can look like "it's not working" when the real issue is the vial. Dosing science itself, separate from purity, is the other half of results: tirzepatide's titration schedule (starting at 2.5 mg weekly, increasing in 2.5 mg increments no faster than every four weeks up to a maximum 15 mg weekly) was specifically designed in the trials to balance effectiveness against GI tolerability ^{[8] [7]}. If you're working out how long a course should run and how titration should be paced, Tirz Rx cycle length and the Tirz Rx dosage calculator walk through that separately from the sourcing question covered here. One practical note: rotating Tirz Rx injection sites (abdomen, thigh, upper arm) affects absorption consistency and comfort, but it doesn't compensate for a genuinely impure or mis-dosed product. Technique and sourcing are separate variables, and people sometimes blame one for problems caused by the other.

What's the honest bottom line on compounded versus branded tirzepatide?

If cost and access weren't factors, FDA-approved Mounjaro or Zepbound is the more defensible choice on purity grounds alone: pre-market CMC review, ongoing CGMP manufacturing oversight, and a manufacturer legally accountable for what's in every vial ^[3]. That's the honest, non-hedged answer. Cost and access are real factors, though, which is why compounded tirzepatide exists at meaningful scale. If you go that route, the purity question isn't rhetorical, it's a checklist: registered 503B facility, batch-specific CoA from a named, accredited lab, clear identity and potency testing method disclosed, and a real prescriber doing actual intake screening for the contraindications above. A provider-reviewed process that connects you with a fulfilling pharmacy partner and keeps that documentation available is a meaningfully different experience than an anonymous storefront selling vials with a stock PDF attached. Tirz Rx's provider-reviewed intake is built around exactly that kind of accountability chain, connecting patients to a fulfilling pharmacy rather than compounding or manufacturing anything itself. Whatever route you choose, don't skip the paperwork check because the price looked good. A cheap vial with no batch-matched CoA and no real clinical screening is the actual risk here, not the concept of compounding itself.

Frequently asked questions

How can I tell if tirzepatide is pure before injecting it?

You generally can't tell by looking; a clear, colorless solution can still be under-concentrated, contaminated, or degraded. The only real verification is a batch-specific Certificate of Analysis from a named, accredited lab (ideally ISO 17025) matched to the lot number of the vial you actually received, showing identity, purity, and sterility testing results.

What purity percentage should tirzepatide have?

Pharmaceutical-grade tirzepatide is generally expected to meet 98% or higher purity by HPLC testing, with defined limits on individual and total impurities under USP compendial standards. A marketing claim of "99.9% pure" with no batch-specific documentation should be treated skeptically regardless of the number.

Is compounded tirzepatide FDA-approved?

No. Only Mounjaro (type 2 diabetes) and Zepbound (chronic weight management) are FDA-approved tirzepatide products. Compounded tirzepatide is made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities and is not individually reviewed or approved by FDA before reaching patients.

Why did FDA remove tirzepatide from the shortage list?

FDA removed tirzepatide from its drug shortage database in December 2024 after determining Lilly's supply of Mounjaro and Zepbound could meet demand. That removal narrowed the legal basis many compounding pharmacies had used to produce tirzepatide copies during the shortage period.

What is a Certificate of Analysis and why does it matter?

A Certificate of Analysis (CoA) is a lab report for one specific manufacturing batch, showing test results for identity, potency, purity, and sterility. It matters because it's the only concrete evidence of what's actually in a given lot; a generic or undated CoA proves very little about the vial in front of you.

What's the difference between a 503A and 503B compounding pharmacy?

A 503A pharmacy compounds for an individual patient prescription and is regulated mainly by state boards of pharmacy. A 503B outsourcing facility registers with FDA, can produce larger batches without patient-specific prescriptions, and follows CGMP-like standards with more routine FDA inspection oversight.

Can tirzepatide cause thyroid cancer?

Mounjaro and Zepbound carry an FDA boxed warning for thyroid C-cell tumors based on rodent studies; it's unknown whether this occurs in humans. Tirzepatide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

How much weight loss does tirzepatide actually produce in trials?

In SURMOUNT-1 (NCT04184622), adults without diabetes lost an average of 20.9% body weight at the 15 mg dose over 72 weeks versus 3.1% on placebo. Results at lower doses and in patients with type 2 diabetes were somewhat lower.

How should tirzepatide be stored to preserve purity?

Unopened Zepbound vials or pens can be refrigerated (36°F to 46°F) until the printed expiration date, or kept at room temperature for up to 21 days per manufacturer labeling. Compounded products follow the specific beyond-use date set by the compounding pharmacy, which is typically shorter.

Does a low price mean a tirzepatide product isn't pure?

Not necessarily, but it's a legitimate reason to ask harder questions. Low price with no batch-specific CoA, no named accredited lab, and no real clinical intake process is a meaningfully higher-risk combination than a similarly priced product that provides all three.

What side effects should I expect regardless of where I get tirzepatide?

Gastrointestinal side effects (nausea, diarrhea, constipation, vomiting) are the most common, especially during dose increases. These occur in FDA-approved and compounded versions alike because they're pharmacologic effects of the drug itself, not related to sourcing or purity.

Should I trust a seller marketing tirzepatide as "research use only"?

Be cautious. This labeling is often a legal workaround for selling to individual consumers without clinical oversight, prescriptions, or verified batch testing, rather than a genuine research context. Products sold this way typically carry no accountable prescriber and no reliable purity documentation.

Sources

1. FDA, New Drug Application review process overview: FDA reviews chemistry, manufacturing, and controls including purity as part of NDA approval
2. FDA, Drug Shortages Database (tirzepatide removal, Dec 2024): FDA resolved the tirzepatide shortage in December 2024, changing the legal basis for compounding
3. FDA, 21 CFR Part 211 Current Good Manufacturing Practice for Finished Pharmaceuticals: CGMP regulations govern ongoing manufacturing quality control for approved drug products
4. FDA, Human Drug Compounding under Section 503B FD&C Act: 503B outsourcing facilities register with FDA and are subject to routine inspection unlike 503A pharmacies
5. USP, Compounding Standards and Tirzepatide Quality Resources: USP develops testing methods and quality standards used to assess compounded drug purity
6. ANSI National Accreditation Board, ISO/IEC 17025 accreditation program: ISO/IEC 17025 is the international standard for testing and calibration laboratory competence
7. FDA, Zepbound Prescribing Information: Tirzepatide dosing is titrated from 2.5 mg to a maximum of 15 mg weekly, and storage conditions are specified
8. FDA, Mounjaro Prescribing Information: Tirzepatide titration schedule and dosing increments for type 2 diabetes indication
9. NEJM, SURMOUNT-1 trial (Jastreboff et al., 2022), NCT04184622: SURMOUNT-1 showed 20.9% mean weight loss at 15 mg tirzepatide over 72 weeks versus 3.1% placebo
10. NEJM, SURPASS-2 trial (Frias et al., 2021), NCT03987919: SURPASS-2 compared tirzepatide to semaglutide 1 mg for glycemic and weight outcomes in type 2 diabetes